home / stock / lbtsf / lbtsf short
Short Information | Almirall Sa Ord (OTCMKTS:LBTSF)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 33,465 |
Total Actual Volume | 33,465 |
Short Trends | |
---|---|
Cover Days | 0 |
Short Days | 20 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 1,673 |
Average Short Percentage | 100.00% |
Is there a LBTSF Short Squeeze or Breakout about to happen?
See the LBTSF Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
04-01-2024 | $0 | $9.51 | $0 | $0 | 6 | 6 | 100% |
09-13-2023 | $10.18 | $10.18 | $10.18 | $10.18 | 100 | 100 | 100% |
07-05-2023 | $0 | $8.85 | $0 | $0 | 34 | 34 | 100% |
06-21-2023 | $8.85 | $8.85 | $8.85 | $8.85 | 400 | 400 | 100% |
04-24-2023 | $0 | $9.68 | $0 | $0 | 25,000 | 25,000 | 100% |
12-01-2022 | $9.68 | $9.68 | $9.68 | $9.68 | 106 | 106 | 100% |
09-09-2022 | $9.28 | $9.28 | $9.28 | $9.28 | 1,000 | 1,000 | 100% |
05-06-2022 | $12.29 | $12.29 | $12.29 | $12.29 | 400 | 400 | 100% |
03-25-2022 | $13.85 | $13.85 | $13.85 | $13.85 | 100 | 100 | 100% |
11-29-2021 | $12.5 | $12.5 | $12.5 | $12.5 | 500 | 500 | 100% |
10-08-2021 | $15.3 | $15.3 | $15.3 | $15.3 | 200 | 200 | 100% |
04-07-2021 | $15 | $15 | $15 | $15 | 1,000 | 1,000 | 100% |
04-06-2021 | $15.1 | $15.2 | $15.2 | $15.1 | 1,300 | 1,300 | 100% |
10-28-2020 | $10.6 | $10.6 | $10.6 | $10.6 | 1,000 | 1,000 | 100% |
10-05-2020 | $12.3 | $12.3 | $12.3 | $12.3 | 571 | 571 | 100% |
08-04-2020 | $11.3 | $11.3 | $11.3 | $11.3 | 1,041 | 1,041 | 100% |
01-27-2020 | $15.96 | $15.96 | $15.96 | $15.96 | 100 | 100 | 100% |
01-22-2020 | $N/A | $16.90 | $N/A | $N/A | 11 | 11 | 100% |
01-17-2020 | $N/A | $16.90 | $N/A | $N/A | 25 | 25 | 100% |
01-16-2020 | $16.90 | $16.90 | $16.90 | $16.90 | 571 | 571 | 100% |
News, Short Squeeze, Breakout and More Instantly...
Almirall Sa Ord Company Name:
LBTSF Stock Symbol:
OTCMKTS Market:
Almirall’s sustainability strategy focuses on five pillars: Planet, People, Patients, Partners and Principles defining clear targets and measurements Among other commitments, Almirall aims to – by 2030 - reduce absolute direct greenhouse gas emissions by 50%, minimize the ge...
Almirall presented the interim Week 52 results of the POSITIVE clinical study at the IFPA Conference 2024, showing the benefits of the effective treatment with Ilumetri (tildrakizumab) in patients with moderate to severe psoriasis achieving improvement of physical symptoms and overall wellbeing. ...
Positive trajectory with Net Sales increase by 6.6% to a total of €247.4 MM, EBITDA increase of 1.4% YoY to a total of €52.5 MM driven by higher overall sales Performance driven by biologics as key growth engines, with Ilumetri ® showing 30% increase in sales vs Q1 ...